Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7 - Gilde Healthcare

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

August 31, 2023
Issy-les-Moulineaux, France

Withings introduces the hybrid watch that watches your health day and night with new capabilities to monitor body temperature 24/7, heart rate variability, respiratory rate and female menstrual cycles

In 2014, Withings, a pioneer of the digital health movement, announced the world’s first hybrid watch. Today it furthers its leadership of the hybrid connected watch sector, unveiling the latest generation of its groundbreaking ScanWatch. With two new models, ScanWatch 2 and ScanWatch Light, Withings provides a lineup to meet multiple lifestyle and health needs. ScanWatch 2 becomes its flagship health tracker, optimized for continuous health assessments of advanced metrics, while ScanWatch Light offers a robust assessment of daily health at a price point that is as attractive as its design.

The ScanWatch lineup is a significant disrupter in the smartwatch sector, offering an elegant alternative to strapping a mini smartphone to the wrist. The truly beautiful timepieces offer some of the most advanced health-tracking capabilities on the market and are packed full of technology to make continuous measurements autonomous and effortless without the need to charge batteries daily.

ScanWatch 2 – Tech for 24/7 Tracking
The original ScanWatch is FDA-cleared for atrial fibrillation detection using ECG and for oxygen saturation of arterial hemoglobin (SpO2) from the wrist while also performing multiple wellness functions such as monitoring sleep quality, physical activity and a range of cardiovascular measurements.
ScanWatch 2 goes further with a host of additional sensors and software that are optimized to facilitate continuous health monitoring and precise assessment of new health metrics. Its additional capabilities include variation of the baseline body temperature, female cycle tracking, heart rate variability, and the automatic recognition of 40+ activities.

ScanWatch 2 is designed to enable health tracking to take place day and night and over sustained periods of time. Thanks to a market-leading 30-day battery life, and the ability to continuously track more advanced health metrics than ever before, Withings ScanWatch 2 becomes a real guardian of health. It provides greater insights to help people take proactive control of it through a beautifully designed, analog stylish, lightweight watch that can easily grace any outfit.

Drawing on over 10 years of experience in tracking the health vitals on the wrist of millions of people, ScanWatch 2 becomes the new flagship for Withings hybrid watches and benefits from a significant upgrade in sensor hardware and HealthSenseTM – Withings’ proprietary operating system. It becomes its most precise tracking device to date thanks to state-of-the-art sensors and algorithms which provide more accuracy to track body temperature from a wearable than current solutions on the market, a MultiWave PPG Sensor that adds new capabilities and accuracy thanks to the use of 4 wavelengths and 16 PPG channels, and a High Dynamic Range Accelerometer that adds additional directional sensors allowing more precise identification and automatic tracking of activities and workouts as well as more sports to be automatically detected.

As well as measuring a greater array of medical stats, updates to the Withings HealthSense OS mean ScanWatch 2 is more efficient. HealthSense sees an update to PowerSense Pro, part of the OS that identifies the best time to launch a health measurement and send heart health1 notifications that maximize battery life and ensure recording accuracy. Power is further extended with the ability to detect when the watch is not worn, thereby avoiding unnecessary tracking. The OS updates also allow more readings and inputs to be actioned directly on the watches as well as within the Withings App while also enabling Withings to keep launching new features updated to always offer users a top-notch product and health experience.

Turning Up The Heat in continuous Body Temperature Tracking
Withings takes a new approach to body temperature tracking thanks to the TempTech24/7 module. It combines a breakthrough miniaturized heat flux sensor (measuring energy transit) with a high-accuracy temperature sensor (measuring ambient & skin temperature) alongside heart rate and accelerometer input calibrations to deliver a best-in-class body temperature variation assessment.
ScanWatch 2 is able to provide baseline fluctuations of day and night body temperature which may
indicate the onset of an illness or other health condition, as well as boosts the ability to manage performance and recovery through workout temperature variation zones.

The Cycle of Life
The ability for women to add menstrual cycles straight on a smartwatch is a new feature that provides an enhanced and more seamless approach to holistic health, allowing menstrual cycles to be tracked as a health metric. Women are able to log their menstrual cycle stages, including symptoms, flow, and period dates, as well as record moods and emotions and to have a view on where they are in their cycle. The new lineup of ScanWatch will then use this data to predict future period dates helping women create personal routines that align with their monthly needs and optimize sleep, activity, and nutrition all month long. With the next generation of ScanWatch, users will be able to manually log information directly on the watch or via the Withings App. Users of previous models of ScanWatch will have the ability to log information on the Withings App.

ScanWatch Light – Light by Name but Not by Nature
The ScanWatch new lineup also includes ScanWatch Light, the most affordable model in the range providing users who are at the beginning of their health journey with better and more advanced health tracking for non-stop daily care. Like ScanWatch 2, it provides a comprehensive overview of heart health, activity and cycle tracking, and sleep monitoring. Sharing the same HealthSense technology, it is optimized for around-the-clock monitoring for up to 30 days.

Health Specs For All Needs
While most smartwatches prioritize productivity, communication, and entertainment, Withings watches and their accompanying app have health as their primary focus. The Withings App provides users with an unparalleled 360-degree health data hub, incorporating innovative measurements, comprehensive health assessments through the health improvement score (including sub-scores related to activity, heart health, body metrics, and sleep), actionable insights, and educational content from medical and fitness expert and motivational messages. It also enables the creation of individual health reports that can be shared with physicians on top of a specific report about menstrual cycles for women.
“The extraordinary new ScanWatch are timepieces that represent a remarkable fusion of cutting-edge technology and timeless design, setting a new standard for health monitoring and style. With an even greater ability to continuously track advanced health metrics that were once only available in a clinical setting, we are empowering people to make better health part of their daily lives,” said Eric Carreel, founder and President of Withings.

Availability
ScanWatch 2 (38 & 42 mm) is available now for pre-orders on Withings.com priced at 349,95€ with a Silver Black (42mm), silver white (38mm), silver black (38mm) and Rose Gold sand face (38mm) and later on with a Silver white face (42mm) and Rose Gold blue face (38mm). ScanWatch Light sized 37mm is available on pre-orders on Withings.com priced at 249,95€ with a silver black, silver white and rose gold sand face and later on with a light blue and light green face. Both models will be widely available from selected retailers from October 2023. Each model features an OLED grayscale display and are available with optional colored wristbands.

About Withings
Withings created the first smart scale in 2009 and has been the pioneer in connected health ever since.
Its clinically validated and multi-award-winning range is used by millions worldwide and includes smart scales, hybrid watches, blood pressure monitors, sleep analyzers, and more. The team of engineers, data scientists, and healthcare professionals at Withings work alongside clinical experts to make it possible to take medical-grade measurements at home. Withings was the first to bring measurements for pulse wave velocity and electrodermal activity into the home – finding ever more precise ways to measure our health. Withings Health Solutions, its dedicated division serving healthcare professionals across chronic disease prevention and management, remote patient monitoring, clinical research, and more, helps bridge the gap between patients and their care teams.
Withings is dedicated to creating a world where people can see their path to better health and feel supported to pursue it using devices designed to fit beautifully into daily life, supported by information that unlocks long-term health insights and offers programs to create meaningful change.
Find out more at withings.com and connect with us on Facebook, Instagram, or Twitter.

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international growth in the medical imaging market

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in...
December 16, 2024

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first...
December 12, 2024

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital...
December 11, 2024